113 related articles for article (PubMed ID: 984981)
1. Drug metabolism and morphologic changes in the liver of nafenopin-treated rats.
Tuchweber B; Kourounakis P; Latour JG
Arch Int Pharmacodyn Ther; 1976 Aug; 222(2):309-21. PubMed ID: 984981
[TBL] [Abstract][Full Text] [Related]
2. Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response.
Reddy JK; Azarnoff DL; Svoboda DJ; Prasad JD
J Cell Biol; 1974 May; 61(2):344-58. PubMed ID: 4208071
[TBL] [Abstract][Full Text] [Related]
3. Increased hepatotoxicity of carbon tetrachloride by the hypolipidemic drug nafenopin in rats.
Charpentier D; Tuchweber B
Res Commun Chem Pathol Pharmacol; 1982 Jun; 36(3):449-61. PubMed ID: 6289397
[TBL] [Abstract][Full Text] [Related]
4. Effects of the hypolipidemic drug nafenopin on the zona fasciculata of the rat adrenal cortex: a correlated biochemical and stereological study.
Mazzocchi G; Robba C; Rebuffat P; Belloni AS; Nussdorfer GG
Anat Rec; 1982 Nov; 204(3):245-54. PubMed ID: 7158828
[TBL] [Abstract][Full Text] [Related]
5. Effect of the hypolipidemic drug nafenopin (2-methyl-2-(p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy)propionic acid; TPIA; SU-13,437), on the hepatic disposition of foreign compounds in the rat.
Levine WG
Drug Metab Dispos; 1974; 2(2):178-86. PubMed ID: 4150998
[No Abstract] [Full Text] [Related]
6. Effect of nafenopin (SU-13,437) on liver functions. Hepatic uptake and biliary excretion of ouabain in the rat.
Meijer DK; Bognacki J; Levine WG
Drug Metab Dispos; 1975; 3(3):220-5. PubMed ID: 238821
[TBL] [Abstract][Full Text] [Related]
7. Hepatic microbody proliferation and catalase synthesis induced by methyl clofenapate, a hypolipidemic analog of CPIB.
Reddy JK
Am J Pathol; 1974 Apr; 75(1):103-18. PubMed ID: 4825610
[TBL] [Abstract][Full Text] [Related]
8. Effects of the hypolipidemic drug nafenopin on the zona glomerulosa of the rat adrenal cortex: morphological counterparts of functional alterations.
Robba C; Mazzocchi G; Gottardo G; Nussdorfer GG
Anat Anz; 1986; 161(1):35-41. PubMed ID: 3010777
[TBL] [Abstract][Full Text] [Related]
9. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
10. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
Moody DE; Reddy JK
Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):501-10. PubMed ID: 4445568
[No Abstract] [Full Text] [Related]
11. Effect of nafenopin on the uptake of bilirubin and sulfobromophthalein by isolated perfused rat liver.
Gärtner U; Stockert RJ; Levine WG; Wolkoff AW
Gastroenterology; 1982 Dec; 83(6):1163-9. PubMed ID: 6751925
[TBL] [Abstract][Full Text] [Related]
12. Biliary excretion of 3,4-benzpyrene in nafenopin-treated rats.
Levine WG; Bognacki J
J Pharmacol Exp Ther; 1976 Feb; 196(2):486-92. PubMed ID: 1255492
[TBL] [Abstract][Full Text] [Related]
13. Role of fatty acyl coenzyme A oxidase in the efflux of oxidized glutathione from perfused livers of rats treated with the peroxisome proliferator nafenopin.
Conway JG; Neptun DA; Garvey LK; Popp JA
Cancer Res; 1987 Sep; 47(18):4795-800. PubMed ID: 3621175
[TBL] [Abstract][Full Text] [Related]
14. Effect of nafenopin (SU-13437) on liver function. Influence on the hepatic transport of phenolphthalein glucuronide and chlorothiazide.
Uesugi T; Levine WG
Drug Metab Dispos; 1976; 4(2):107-11. PubMed ID: 5253
[TBL] [Abstract][Full Text] [Related]
15. Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital.
Furukawa K; Numoto S; Furuya K; Furukawa NT; Williams GM
Cancer Res; 1985 Oct; 45(10):5011-9. PubMed ID: 2862989
[TBL] [Abstract][Full Text] [Related]
16. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
Reddy J; Svoboda D; Azarnoff D
Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
[No Abstract] [Full Text] [Related]
17. Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
Tuchweber B; Salas M
Arch Toxicol; 1978 Dec; 41(3):223-32. PubMed ID: 736793
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset.
Lake BG; Evans JG; Gray TJ; Körösi SA; North CJ
Toxicol Appl Pharmacol; 1989 Jun; 99(1):148-60. PubMed ID: 2499080
[TBL] [Abstract][Full Text] [Related]
19. Effect of thymectomy on zoxazolamine paralysis and metabolism in untreated and (PCN) pregnenolone-16alpha-carbonitril- or ACTH-pretreated rats.
Szabo S; Kourounakis P; Garg BD; Silva OM
Arch Int Pharmacodyn Ther; 1975 Jun; 215(2):208-14. PubMed ID: 169755
[TBL] [Abstract][Full Text] [Related]
20. A study on cerium-induced liver injury in rats after pretreatment with spironolactone, phenobarbital, pregnenolone-16 alpha-carbonitrile and nafenopin.
Bjondahl K
Arzneimittelforschung; 1978; 28(5):817-9. PubMed ID: 581962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
